A Single-patient Study of Repeat-dose Administration of Prometic

See also
Status	Clinical Trial	Phase
Completed	`NCT02690714` - A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia	Phase 2/Phase 3
Completed	`NCT02312180` - A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency	Phase 1
No longer available	`NCT03642691` - A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

See also

Status

Clinical Trial

Phase

Completed

NCT02690714 - A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

Phase 2/Phase 3

Completed

NCT02312180 - A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency

Phase 1

No longer available

NCT03642691 - A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT03265171
Study type	Expanded Access
Source	Prometic Biotherapeutics, Inc.
Contact
Status	No longer available
Phase

A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms